{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:18:50Z","timestamp":1792030730959,"version":"4.4.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>The choice of treatment strategy in patients with idiopathic pulmonary arterial hypertension (IPAH)\/HPAH\/DPAH (Hereditary pulmonary arterial hypertension\/ Drug-induced pulmonary arterial hypertension) II-III functional class (FC) (WHO) based on an acute vasoreactive testing result (VRT). Positive VRT (VRT+) is an indication for calcium channel blockers therapy. Long-term vasoresponders demonstrate sustained low-risk status and the highest survival among all PH subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>THE STUDY AIMED:<\/jats:title>\n                    <jats:p>To characterize VRT performance in IPAH patients and differences in presentation between patients with positive, negative VRT, and patients with not done VRT due to physicians\u2019 decision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>One hundred and sixty-six adult IPAH patients (44.2 \u00b1 15.3 years, 34 males) comprised into prospective single-center study between 2008 and 2023 years. Inhaled iloprost was used for VRT. Positive VRT was defined with established Sitbon criteria. Standard baseline pulmonary arterial hypertension (PAH) evaluation including cardiopulmonary exercise test (CPET) was performed. Risk status was evaluated using ESC\/ERS (European Society of Cardiology\/European Respiratory Society) risk scale 2015. Survival was assessed with the Kaplan\u2013Mayer method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Eighty-five (51.2%) patients underwent VRT. VRT not done (ND VRT) due to the physicians\u2019 decision in 26.7% patients, due to the technical inability in 15.4% and IV FC (WHO) in 16.2% patients. Positive VRT registered in 26 (15.6%) patients. Patients with negative VRT demonstrated worse hemodynamics and exercise tolerance, higher N-terminal pro-brain-type natriuretic peptide (NT-proBNP) level, and right heart dilatation compared with VRT+. Patients with ND VRT due to the physicians decision were often older than 60 years, had higher body mass index, symptoms of right heart failure, hemoptysis, arrhythmias, high NT-proBNP, and hemodynamic criteria of high risk in comparison with patients with done VRT. Some CPET parameters were similar between VRT + group and patients ND VRT group. Loss of vasoreactivity and PAH worsening were detected in 50% of VRT + patients in a 1.76 year of follow-up. Patients with vasoreactivity loss exhibited the criteria of intermediate risk at a baseline. Five-year survival was 97% in VRT + group in comparison with 61% in VRT \u2212 and 53% in ND VRT group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Physicians\u2019 decision was the most common reason for not doing VRT in IPAH patients. Intermediate high-risk criteria presence at a baseline were associated with not done VRT due to physicians decision, negative VRT, and the vasoreactivity loss during the follow-up. CPET should be used more widely to detect the early signs of PAH progression in low risk or VRT + patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/atm.atm_189_24","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T05:00:12Z","timestamp":1736571612000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Vasoreactive testing prevalence and characteristics in patients with idiopathic pulmonary arterial hypertension"],"prefix":"10.4103","volume":"20","author":[{"given":"Goncharova","family":"Natalia","sequence":"first","affiliation":[{"name":"Department of Noncoronary Disease, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Lapshin","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aelita","family":"Berezina","sequence":"additional","affiliation":[{"name":"Department of Cardiorespiratory Testing, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Zlobina","sequence":"additional","affiliation":[{"name":"Department of Cardiorespiratory Testing, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Ryzhkov","sequence":"additional","affiliation":[{"name":"Department of Magnetic Resonance Imaging, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaneta","family":"Matakaeva","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Andreeva","sequence":"additional","affiliation":[{"name":"Department of Noncoronary Disease, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Moiseeva","sequence":"additional","affiliation":[{"name":"Department of Noncoronary Disease, Almazov National Medical Research Center, Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"e024969","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: Early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCULATIONAHA.122.063821","article-title":"Positive vasoreactivity testing in pulmonary arterial hypertension: Therapeutic consequences, treatment patterns, and outcomes in the modern management era","volume":"149","author":"Gerhardt","year":"2024","journal-title":"Circulation"},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"132043","DOI":"10.1016\/j.ijcard.2024.132043","article-title":"Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment","volume":"406","author":"Hirakawa","year":"2024","journal-title":"Int J Cardiol"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"99","DOI":"10.17116\/medtech20234501199","article-title":"Socio-economic burden of newly diagnosed pulmonary arterial hypertension and early specific treatment initiation impact on the costs in real clinical practice in Russia","volume":"1","author":"Zakiev","year":"2023","journal-title":"Med Technol Assess Choice"},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.pcad.2015.09.006","article-title":"Role of vasodilator testing in pulmonary hypertension","volume":"58","author":"Sharma","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"e12281","DOI":"10.1002\/pul2.12281","article-title":"Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study","volume":"13","author":"Naranjo","year":"2023","journal-title":"Pulm Circ"},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.hlc.2022.09.005","article-title":"Acute vasoreactivity testing and outcomes in pulmonary arterial hypertension: A call for increased testing","volume":"32","author":"Chandrasekara","year":"2023","journal-title":"Heart Lung Circ"},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"R13-20250314","first-page":"62","article-title":"The long-term response to treatment with calcium channel blockers in patients with idiopathic pulmonary arterial hypertension","volume":"18","author":"Kiani","year":"2023","journal-title":"J Tehran Heart Cent"},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.3390\/jcm12175465","article-title":"The current role of cardiopulmonary exercise test in the diagnosis and management of pulmonary hypertension","volume":"12","author":"Pezzuto","year":"2023","journal-title":"J Clin Med"},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"e20220337","DOI":"10.36416\/1806-3756\/e20220337","article-title":"Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension","volume":"49","author":"Piloto","year":"2023","journal-title":"J Bras Pneumol"},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00408-019-00318-0","article-title":"Is there value in repeating inhaled nitric oxide vasoreactivity tests in patients with pulmonary arterial hypertension?","volume":"198","author":"Tooba","year":"2020","journal-title":"Lung"},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"e12152","DOI":"10.1002\/pul2.12152","article-title":"Prognostic value of longitudinal vasoreactivity in pediatric pulmonary hypertension","volume":"12","author":"Evers","year":"2022","journal-title":"Pulm Circ"},{"key":"R18-20250314","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jjcc.2023.01.005","article-title":"Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension","volume":"82","author":"Ishii","year":"2023","journal-title":"J Cardiol"}],"container-title":["Annals of Thoracic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/atm.atm_189_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:41:23Z","timestamp":1787773283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/atm.atm_189_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/atm.atm_189_24","relation":{},"ISSN":["1817-1737","1998-3557"],"issn-type":[{"value":"1817-1737","type":"print"},{"value":"1998-3557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-08-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}